BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hajarizadeh B, Razavi-Shearer D, Merat S, Alavian SM, Malekzadeh R, Razavi H. Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden. Hepat Mon. 2016;16:e37234. [PMID: 27642346 DOI: 10.5812/hepatmon.37234] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Maaroufi A, Vince A, Himatt SM, Mohamed R, Fung J, Opare-Sem O, Workneh A, Njouom R, Al Ghazzawi I, Abdulla M, Kaliaskarova KS, Owusu-Ofori S, Abdelmageed MK, Adda D, Akin O, Al Baqali A, Al Dweik N, Al Ejji K, Al Kaabi S, Al Naamani K, Al Qamish J, Al Sadadi M, Al Salman J, AlBadri M, Al-Busafi SA, Al-Romaihi HE, Ampofo W, Antonov K, Anyaike C, Arome F, Bane A, Blach S, Borodo MM, Brandon SM, Bright B, Butt MT, Cardenas I, Chan HLY, Chen CJ, Chen DS, Chen PJ, Chien RN, Chuang WL, Cuellar D, Derbala M, Elbardiny AA, Estes C, Farag E, Gamkrelidze I, Garcia V, Genov J, Ghandour Z, Ghuloom M, Gomez B, Gunter J, Habeeb J, Hajelssedig O, Hamoudi W, Hrstic I, Hu CC, Huang CF, Hui YT, Jahis R, Jelev D, John AK, Kamel Y, Kao JH, Khamis J, Khattabi H, Khoudri I, Konysbekova A, Kotzev I, Lai MS, Lao WC, Layden J, Lee MH, Lesi O, Li M, Lo A, Loo CK, Lukšić B, Malu AO, Mateva L, Mitova R, Morović M, Murphy K, Mustapha B, Nde H, Nersesov A, Ngige E, Njoya O, Nonković D, Obekpa S, Oguche S, Okolo EE, Omede O, Omuemu C, Ondoa P, Phillips RO, Prokopenko YN, Razavi H, Razavi-Shearer D, Redae B, Reic T, Rinke de Wit T, Rios C, Robbins S, Roberts LR, Sanad SJ, Schmelzer JD, Sharma M, Simonova M, Su TH, Sultan K, Tan SS, Tchernev K, Tsang OTY, Tsang S, Tzeuton C, Ugoeze S, Uzochukwu B, Vi R, Wani HU, Wong VWS, Yacoub R, Yesmembetov KI, Youbi M, Yuen MF, Razavi-Shearer K. Historical epidemiology of hepatitis C virus in select countries-volume 4. J Viral Hepat 2017;24 Suppl 2:8-24. [PMID: 29105285 DOI: 10.1111/jvh.12762] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
2 Hariri S, Sharafkhah M, Alavi M, Roshandel G, Fazel A, Amiriani T, Motamed-Gorji N, Bazazan A, Merat S, Poustchi H, Malekzadeh R. A simple risk-based strategy for hepatitis C virus screening among incarcerated people in a low- to middle-income setting. Harm Reduct J 2020;17:56. [PMID: 32795371 DOI: 10.1186/s12954-020-00400-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Sadeghi A, Amiri R, Akbarpour E, Mirminachi B, Sharifi AH, Merat S. Changes in liver fibrosis in patients with chronic hepatitis C after successful direct-acting antiviral therapy. Int J Clin Pract 2021;75:e14145. [PMID: 33709413 DOI: 10.1111/ijcp.14145] [Reference Citation Analysis]
4 Alavian SM, Sharafi H. Update on Recommendations for the Clinical Management of Hepatitis C in Iran 2017. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.63956] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
5 Moradi G, Hajarizadeh B, Rahmani K, Mohamadi-Bolbanabad A, Darvishi S, Zareie B, Zavareh FA, Sharafi H, Alavian SM, Ramazani R, Eftekhar M, Radfar SR, Piroozi B, Gouya MM. Drug use and risk behaviour profile, and the prevalence of HIV, hepatitis C and hepatitis B among people with methamphetamine use in Iran. Int J Drug Policy 2019;73:129-34. [PMID: 31654935 DOI: 10.1016/j.drugpo.2019.09.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
6 Moradi G, Gouya MM, Azimizan Zavareh F, Mohamadi Bolbanabad A, Darvishi S, Aghasadeghi MR, Nabavi M, Alasvand R, Tashakorian M, Nouri B, Rahmani K, Molaei L. Prevalence and risk factors for HBV and HCV in prisoners in Iran: a national bio-behavioural surveillance survey in 2015. Trop Med Int Health 2018;23:641-9. [PMID: 29698576 DOI: 10.1111/tmi.13065] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
7 Saidi RF, Kazemaini SM, Malekzadeh R. Current Challenges of Liver Transplantation in Iran. Middle East J Dig Dis 2018;10:45-9. [PMID: 29682248 DOI: 10.15171/mejdd.2017.90] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Behzadifar M, Azari S, Gorji HA, Martini M, Bragazzi NL. The hepatitis C virus in Iran: health policy, historical, ethical issues and future challenges. J Prev Med Hyg 2020;61:E109-18. [PMID: 32490276 DOI: 10.15167/2421-4248/jpmh2020.61.1.1438] [Reference Citation Analysis]
9 Babaei AH, Safarpour AR, Fattahi MR, Ahmadi V. Epidemiology of Hepatitis C Virus Infection Among 1,959 Patients in Shiraz, Southern Iran, Between 1991 and 2016. Arch Clin Infect Dis 2020;15. [DOI: 10.5812/archcid.98849] [Reference Citation Analysis]
10 Getie B, Ayalew G, Amsalu A, Ferede G, Yismaw G, Tessema B. Seroprevalence and Associated Factors of Hepatitis B and C Virus Among Pulmonary Tuberculosis Patients Attending Health Facilities in Gondar Town, Northwest Ethiopia. Infect Drug Resist 2021;14:3599-608. [PMID: 34511951 DOI: 10.2147/IDR.S327503] [Reference Citation Analysis]
11 European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol 2017;2:325-36. [PMID: 28397696 DOI: 10.1016/S2468-1253(17)30045-6] [Cited by in Crossref: 145] [Cited by in F6Publishing: 60] [Article Influence: 29.0] [Reference Citation Analysis]
12 Hariri S, Alavi M, Roshandel G, Mohammadi Z, Fazel A, Amiriani T, Bazazan A, Motamed-Gorji N, Sohrabpour A, Merat S, Poustchi H, Malekzadeh R. An intervention to increase hepatitis C virus diagnosis and treatment uptake among people in custody in Iran. Int J Drug Policy 2021;95:103269. [PMID: 33991887 DOI: 10.1016/j.drugpo.2021.103269] [Reference Citation Analysis]
13 Behzadifar M, Azari S, Gorji HA, Rezapour A, Bragazzi NL. The challenges of hepatitis C management in Iran: A qualitative study with patients. Int J Health Plann Manage 2020;35:e56-65. [PMID: 31679166 DOI: 10.1002/hpm.2927] [Reference Citation Analysis]
14 Sarvari J, Mansouri M, Hashempoor T, Hosseini SY, Moattari A, Pirbonyeh N, Dowran R, Moayedi J, Musavi Z, Fattahi M. Association of Genotype and Haplotype of IL-28B Gene with Hepatitis C Infection Outcome in Iran: Spontaneous Clearance Versus Chronic Infection. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.45745] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
15 Pouri AA, Ghojazadeh M, Pourasghari B, Baiaz B, Soghra Hamzavi F, Somi MH. Seroepidemiology and risk factors of hepatitis C virus infection in East Azerbaijan, Iran: a population-based Azar Cohort study. Caspian J Intern Med 2019;10:326-31. [PMID: 31558996 DOI: 10.22088/cjim.10.3.326] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Hecht R, Hiebert L, Spearman WC, Sonderup MW, Guthrie T, Hallett TB, Nayagam S, Razavi H, Soe-Lin S, Vilakazi-Nhlapo K, Pillay Y, Resch S. The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up. Health Policy Plan 2018;33:528-38. [PMID: 29529282 DOI: 10.1093/heapol/czy018] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
17 Ziaee M, Hajihosseini M. Hepatitis Awareness Bus: A Model for Finding Unknown Hepatitis B and C Infections. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.11719] [Reference Citation Analysis]
18 Taherkhani R, Farshadpour F. Lurking epidemic of hepatitis C virus infection in Iran: A call to action. World J Hepatol 2017; 9(24): 1040-1042 [PMID: 28932350 DOI: 10.4254/wjh.v9.i24.1040] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
19 Pourkarim MR, Razavi H, Lemey P, Van Ranst M. Iran's hepatitis elimination programme is under threat. Lancet 2018;392:1009. [PMID: 30264697 DOI: 10.1016/S0140-6736(18)31810-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
20 Alavian SM, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimi Daryani N, Merat S, Mohraz M, Mardani M, Fattahi MR, Poustchi H. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. Hepat Mon. 2016;16:e40959. [PMID: 27799966 DOI: 10.5812/hepatmon.guideline] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 7.0] [Reference Citation Analysis]
21 Moghimi M, Tavakoli F, Doosti M, Ahmadi-Vasmehjani A, Akhondi-Meybodi M. Correlation between interleukin-28 gene polymorphism with interleukin-28 cytokine levels and viral genotypes among HCV patients in Yazd, Iran. BMC Res Notes 2019;12:626. [PMID: 31551080 DOI: 10.1186/s13104-019-4651-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Tasavon Gholamhoseini M, Sharafi H, Hl Borba H, Alavian SM, Sabermahani A, Hajarizadeh B. Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study. BMJ Open 2022;12:e058757. [PMID: 35676019 DOI: 10.1136/bmjopen-2021-058757] [Reference Citation Analysis]
23 Anushiravani A, Ghajarieh Sepanlou S. Burden of Liver Diseases: A Review from Iran. Middle East J Dig Dis 2019;11:189-91. [PMID: 31824620 DOI: 10.15171/mejdd.2019.147] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
24 Sarvari J, Dowran R, Hosseini SY, Fattahi MR, Erfani N. Association of PD-1 gene with outcome of hepatitis C virus infection. EXCLI J 2018;17:935-44. [PMID: 30564072 DOI: 10.17179/excli2018-1394] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
25 Hajarizadeh B. Generic Direct Acting Antiviral Treatment: The First Step Towards Elimination of Hepatitis C in Iran. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.45788] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
26 Cuypers L, Thijssen M, Shakibzadeh A, Deboutte W, Sarvari J, Sabahi F, Ravanshad M, Pourkarim MR. Signature of natural resistance in NS3 protease revealed by deep sequencing of HCV strains circulating in Iran. Infect Genet Evol 2019;75:103966. [PMID: 31323326 DOI: 10.1016/j.meegid.2019.103966] [Reference Citation Analysis]
27 Alavi M, Poustchi H, Merat S, Kaveh-Ei S, Rahimi-Movaghar A, Shadloo B, Hajarizadeh B, Grebely J, Dore GJ, Malekzadeh R. An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study. Int J Drug Policy 2019;72:99-105. [PMID: 31303262 DOI: 10.1016/j.drugpo.2019.07.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
28 Karimi-Sari H, Rezaee-Zavareh MS, Alavian SM. Street and labour children; special group for elimination of viral hepatitis in Iran. Sex Transm Infect 2017;93:38. [PMID: 28100760 DOI: 10.1136/sextrans-2016-052890] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Dehghan Manshadi SA, Merat S, Mohraz M, Rasoolinejad M, Sali S, Mardani M, Tabarsi P, Somi MH, Sedghi R, Tayeri K, Nikbin M, Karimi J, Sharifi AH, Kalantari S, Norouzi A, Merat D, Malekzadeh Z, Mirminachi B, Poustchi H, Malekzadeh R. Single-pill sofosbuvir and daclatasvir for treating hepatis C in patients co-infected with human immunodeficiency virus. Int J Clin Pract 2021;75:e14304. [PMID: 33930223 DOI: 10.1111/ijcp.14304] [Reference Citation Analysis]
30 Moradi G, Jafari S, Zarei B, Mahboobi M, Azimian Zavareh F, Molaeipoor L, Mohamadi Bolbanabad A, Darvishi S, Aghasadeghi MR, Tashakorian M, Gouya MM. Prevalence and Risk Factors for Hepatitis B and Hepatitis C Exposure in Iranian Prisoners: A National Study in 2016. Hepat Mon 2019;19. [DOI: 10.5812/hepatmon.91129] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
31 Saidi RF. Liver Transplantation: What Every Gastroenterologist Should Know about It. Middle East J Dig Dis 2018;10:69-74. [PMID: 30013754 DOI: 10.15171/mejdd.2018.93] [Reference Citation Analysis]
32 Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161-176. [PMID: 28404132 DOI: 10.1016/s2468-1253(16)30181-9] [Cited by in Crossref: 1051] [Cited by in F6Publishing: 472] [Article Influence: 175.2] [Reference Citation Analysis]
33 Wasitthankasem R, Vichaiwattana P, Siripon N, Posuwan N, Auphimai C, Klinfueng S, Thanetkongtong N, Vuthitanachot V, Saiyatha S, Thongmai C, Sochoo S, Pongsuwan N, Poovorawan K, Tangkijvanich P, Poovorawan Y. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study. PLoS One 2018;13:e0196301. [PMID: 29689073 DOI: 10.1371/journal.pone.0196301] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
34 Karimi-sari H, Tajik M, Bayatpoor ME, Sharafi H, Alavian SM. Public Awareness Campaign and Knowledge of Iranian (Bio)Medical Students Regarding Hepatitis B and C Infections. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.45929] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]